SCHEMBL26428969

SCHEMBL26428969

CCOC(=O)c1ccc(C)c(C2CCN(C(=O)OC(C)(C)C)C2)c1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.47
ALDH1A1 P00352 2/20 0.47
KMT2A Q03164 2/20 0.47
TP53 P04637 1/20 0.47
POLB P06746 1/20 0.47
MEN1 O00255 1/20 0.47
LMNA P02545 1/20 0.47
GAA P10253 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
MAPT P10636 2/20 0.47
HPGD P15428 2/20 0.46
KDM4E B2RXH2 2/20 0.46
FDFT1 P37268 1/20 0.46
PDE4B Q07343 1/20 0.45
GPR119 Q8TDV5 3/20 0.45
ATM Q13315 1/20 0.44
THRB P10828 1/20 0.43
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26428976 1.00 NPSR1 (0.47) NPSR1ALDH1A1KMT2ATP53POLB
SCHEMBL26092608 1.00 NPSR1 (0.47) NPSR1ALDH1A1KMT2ATP53POLB
SCHEMBL31015904 1.00 NPSR1 (0.47) NPSR1ALDH1A1KMT2ATP53POLB
SCHEMBL31015900 1.00 NPSR1 (0.47) NPSR1ALDH1A1KMT2ATP53POLB
SCHEMBL30349607 1.00 NPSR1 (0.47) NPSR1ALDH1A1KMT2ATP53POLB
SCHEMBL30728812 0.90 PDE4B (0.54) NPSR1ALDH1A1KMT2ATP53POLB
SCHEMBL26093038 0.86 FDFT1 (0.46) ALDH1A1POLBSMN1; SMN2MAPTKDM4E
SCHEMBL26092030 0.86 FDFT1 (0.46) ALDH1A1POLBSMN1; SMN2MAPTKDM4E
SCHEMBL31386285 0.86 PDE4B (0.53) NPSR1ALDH1A1KMT2ATP53POLB
SCHEMBL8040438 0.83 NAMPT (0.54) NPSR1ALDH1A1KMT2ATP53POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240425482-A1 PYRROLIDINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-12-26 US disclosed
EP-4419516-A1 PYRROLIDINE DERIVATIVES AS DDRS INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2024-08-28 EP disclosed
WO-2023066834-A1 PYRROLIDINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2023-04-27 WO disclosed
WO-2023066834-A1 PYRROLIDINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2023-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240425482-A1 PYRROLIDINE DERIVATIVES AS DDRS INHIBITORS DDR1, DDR2, DDRGK1 NPSR1 1230/4885ALDH1A1 3779/4885KMT2A 3730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.